Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

ENTERING INTO AN EXCLUSIVE PROMOTION SERVICES AGREEMENT WITH LYNK PHARMACEUTICALS IN RESPECT OF DERMATOLOGICAL INDICATIONS OF ZEMPROCITINIB

This announcement is made by Simcere Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on November 2, 2026, the Group further expanded the collaboration with Lynk Pharmaceuticals (Zhejiang) Co., Ltd. ("**Lynk Pharmaceuticals**") in respect of zemprocitinib, a selective JAK1 inhibitor. The Group will obtain the exclusive commercialization rights to zemprocitinib in Greater China for the treatment of adult moderate-to-severe atopic dermatitis ("**AD**") and other dermatological indications.

The Group entered into a collaboration with Lynk Pharmaceuticals in March 2022 and obtained the exclusive commercialization rights to zemprocitinib in Greater China for the treatment of rheumatoid arthritis ("**RA**") and ankylosing spondylitis ("**AS**"). This collaboration will further expand the commercial potential of zemprocitinib and strengthen the Group's product portfolio in the field of autoimmune diseases.

ABOUT ZEMPROCITINIB

Zemprocitinib is a highly selective, oral, second-generation JAK1 inhibitor independently developed by Lynk Pharmaceuticals. It is currently being developed for the treatment of inflammatory and autoimmune diseases, including RA, AD and AS. Zemprocitinib has completed a pivotal Phase III clinical study for AD, and the new drug application (NDA) for the treatment of moderate-to-severe AD was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in April 2026. The Phase III clinical study of zemprocitinib for the treatment of RA has also been completed, while the Phase III clinical development program for AS is ongoing.

ABOUT LYNK PHARMACEUTICALS

Lynk Pharmaceuticals is a clinical-stage innovative drug company focused on autoimmune and inflammatory diseases, committed to addressing unmet clinical needs through first-in-class innovation, developing differentiated small-molecule therapies, and providing superior oral alternatives to biologics. Lynk Pharmaceuticals was founded by senior R&D leaders from globally renowned pharmaceutical companies such as Pfizer, MSD, and Johnson & Johnson, focusing on the JAK-STAT and expanding to TYK2 signaling pathways, and mastering targeted protein degradation.

ABOUT THE GROUP

The Company is an innovation and R&D-driven pharmaceutical company and the Group has established a "State Key Laboratory of Neurology and Oncology Drug Development". The Group focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of "for patients, for life". Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, November 2, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. TANG Renhong as the non-executive Director; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.